Late Thursday night, shares of NPS Pharma (NPSP) sank as its partner GlaxoSmithKline (GSK) - Get Report decided to prematurely stop a midstage study of an osteoporosis drug that was being developed as a joint venture. Glaxo decided to terminate the study of Ronacaleret in postmenopausal women with osteoporosis earlier than expected due to an observed lack of efficacy.
Weak-handed investors clearly over-reacted as they dumped the stock in the after-hours market, to the tune of almost 20%. By all accounts, this is a massive buying opportunity, and here is why:
1. Ronacaleret, one of nine drugs in NPS' pipeline, is not even considered a cash flow item to the company.
2. Glaxo was never really a partner. Rather, in 1993, it bought the rights to a drug that is now obsolete.
Stockpickr is a wholly owned subsidiary of TheStreet.com.